Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed

Seres Therapeutics, Inc.

2025-Q2 EPS reported $1.47

Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.
Received $25M Nestlé installment in July; expects cash runway into Q1 2026.
Co-CEOs Thomas DesRosier and Marella Thorell appointed Aug 1 after prior CEO Eric Shaff departed.
SER-155 Phase 2 protocol submitted to FDA for BSI prevention in allo-HSCT; awaiting FDA feedback.
Engaging with multiple parties on partnerships, out-licensing, or mergers to secure capital.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.